In this case, the essential and novel possibility consist in the fact that antitumor action of CX-5461 can be applied not only in multiple myeloma but also in other c-Myc-driven cancers that additionally can be drug-resistant (Lee at al. 2017b). Here, MYC is linked to plasma cell myeloma.